

# Partnership for Global Impact on Sustainable Vaccine Manufacturing

September 19th, 2023

**Roy Himawan**

Director of Pharmaceutical and Medical Device Resilience

**Ministry of Health  
Republic of Indonesia**



# Background

Pandemic has taught us lessons

- 1. Even though we have the capacity to vaccinate, we can not do anything without the vaccine**  
*HIC-UMIC had vaccinate more than 70% of their population, LMIC (55%) and LIC (16%) left behind<sup>1</sup>*
- 2. Unequal capacity of research and clinical trial led to unequal opportunity to develop and master the technology**  
*While HICs only make up ~16% of the world population, >50% of global clinical trials are conducted in these countries<sup>2</sup>*
- 3. Discrepancy on research and manufacturing capacity between LMIC and HIC**  
*LMICs dominated the highest percentage of deaths for vaccine preventable diseases (VPDs) but lacking the capability to develop the proper vaccines, while HICs showed low cases or insignificant numbers of deaths for VPDs but has the capability to develop and produce the vaccines<sup>3</sup>*
- 4. Regionalized approach is another key to accelerate health system strengthening**  
*Regional investments in vaccine R&D, manufacture, and NRA capacity building would cost less than 1 percent of annual government expenditure on health while offering four-fold higher cost benefit ratios compared to investments and benefits limited to national level<sup>4</sup>*

Source:

1. UNDP - Global dashboard for vaccine equity (as of 11-01-2023)
2. IQVIA, TBI, 2023
3. Based on literature review of vaccine RnD and manufacturing capacity of G20 countries
4. World Bank, 2023

# We have done several

But there is another more to catch-up

## 1. We are building the capacity to develop latest vaccine platform

*Indonesia is now able to develop mRNA platform, with viral vector platform on the pipeline, equipping the existing capacity on conventional vaccine platform*

## 2. We are developing partnership between national vaccine manufacturers and global vaccine manufacturers

*Understanding the nature of technology, and driving by strong affirmation on local capacity, we urge global players to partner with locals in providing vaccine for routine immunization*

## 3. We are providing opportunities for manufacturers to grow with the support of credible financing entities

*Several financing entities are willing to participate in health sector growth, providing support for manufacturers to uplift their capacity with those needed in-country*

## 4. We are facilitating research partnership between local researcher and global organizations

*Working between researchers to develop TB vaccine clinical trials, Dengue vaccine trials, Malaria vaccine trials, and newest therapeutic agent trials*

## 5. We are updating the regulation to enhance these partnership

*Government and Parliament had passed new Health Bill that strongly support the enhancement of research and manufacturing capacity*



# And to level up ...

## Partnership is need to be sustainable

1. We should agree on a realistic regional approach to identify and prioritize the low-hanging fruit of vaccine security, breaking measures down into smaller steps. The region could benefit from exploring new developments such as plug and play technologies in vaccine manufacture, and artificial intelligence in new vaccine and biological development. This will substantially reduce capital investments and provide more flexibility to use the same platforms for different vaccines and biologicals.
2. Regional partnership should address and maximize the opportunity on achieve positive results on:
  - a. **Regulatory harmonization:** shared understanding of the common technical dossier across ASEAN regulators, agree on collaborative procedures for authorization, improve the convergence of the assessment and issuance process of market authorization, and twinning with the highest-rated NRA
  - b. **Regional human resource capacity building:** projecting HR demand over a 5- to 10 year period to justifies investments in higher education and postgraduate training, existing hubs can be leveraged as concentrations of expertise
  - c. **Regional platform for public-private dialogue:** An established repository of incentives, innovations, and emerging lessons offered by region member countries to promote private sector investments in vaccine





KEMENTERIAN  
KESEHATAN  
REPUBLIK  
INDONESIA

**#** bangga  
melayani  
bangsa